Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

167 results about "Isolated cell" patented technology

Methods and compositions for generating vascular leptomeningeal cells

Methods for generating human vascular leptomeningeal cells (VLMCs) from human oligodendrocyte progenitor cells (OPCs) are provided using chemically-defined culture media that allow for generation of differentiated cells in a 34-day culture protocol. Methods of generating human VLMCs from human pluripotent stem cells using chemically-defined culture media in a 40 day culture protocol are also provided. Culture media, isolated cell populations, and kits are also provided.
Owner:TRAILHEAD BIOSYSTEMS INC

Genetically modified anti-third party central memory T cells and use of same in immunotherapy

An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is described. Methods of generating same and using same are also described.
Owner:YEDA RES & DEV CO LTD

Methods for detecting and isolating extracellular vesicles

The disclosure relates to method and kits for highly specific detection and quantification of extracellular vesicles (EVs) by targeting at least two EV surface markers using binding reagents. The binding reagents contain hybridisation sequences and primer binding regions, the hybridisation sequences are ligated and amplified using primers. The disclosure further relates to methods and kits for isolating EVs using capture entities, splint entities and staple entities wherein the capture entity comprises a labile linkage.
Owner:MESO SCALE TECH LLC

TLS structure sketching system and method based on artificial intelligence

The invention relates to the field of medical image processing, and particularly discloses a TLS structure sketching system and method based on artificial intelligence, and the method comprises the steps: S1, image preprocessing: carrying out the standardization processing of an input HE staining section image, firstly separating cell nucleus and cytoplasm staining components through a color deconvolution algorithm, and highlighting the nucleoplasm contrast of lymphocytes; then strengthening the cell contour boundary by adopting an edge detection algorithm, and connecting the fracture edge through morphological operation to form a continuous and clear cell boundary mask; s2, morphological feature extraction: performing single cell segmentation based on the preprocessed image, and extracting geometric features and texture features of each cell; through machine learning model training, distinguishing lymphocytes and non-lymphocytes according to the characteristics, and generating a lymphocyte distribution probability graph; and S3, preliminarily identifying the aggregated area. By adopting the technical scheme of the invention, the TLSs differentiation stage can be identified, and the identification accuracy can be improved by combining morphological characteristics and spatial distribution characteristics.
Owner:FUJIAN PROVINCIAL HOSPITAL

3d-printed skin model using personalized decellularized ecm

The present invention relates to a method for producing a skin tissue model, comprising: (a) isolating and culturing fibroblasts and keratinocytes from skin tissue; (b) preparing a bioink composition for a dermal layer and a bioink composition for an epidermal layer, the bioink composition containing the isolated cells; and (c) producing a skin tissue model using the bioink composition for a dermal layer and the bioink composition for an epidermal layer.
Owner:EWHA UNIV IND COLLABORATION FOUND +1

Methods and compositions for generating somatostatin+ interneurons from human forebrain neural progenitor cells

PCT designated stage expiredWO2025170620A9Culture processNervous system cellsInterneuronNeuron
Methods for generating mature somatostatin+ interneurons from human forebrain neural progenitor cells are provided using chemically-defined culture media in a two-stage culture protocol. The mature somatostatin+ interneurons are generated from medial ganglionic eminence neural progenitor cells (MGE-NPCs), which themselves are differentiated from pluripotent stem cells. Culture media, isolated cell populations and kits are also provided.
Owner:TRAILHEAD BIOSYSTEMS INC

Gas-filled microvesicles with ligand

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.
Owner:BRACCO SUISSE SA

Cell culture vessel, cell detachment method, and cell manufacturing method

To provide: a cell culture vessel that can achieve both detachability and proliferation ability, that is, can facilitate cell detachment without reducing the proliferation ability of cells; and a cell detachment method using the cell culture vessel, provided is a cell detachment method of detaching, through use of a culture vessel having a periodic recess / protrusion pattern on a culture surface, comprising a detachment step of: causing a vibrating unit in which, when an observation image of a cross section perpendicular to the culture surface is obtained, a length Lcp of a contour of the cell on the culture surface side in a measurement region of the observation image and a length Lf of the measurement region in a direction parallel to the culture surface satisfy Lcp>Lf; and transmitting the ultrasonic vibration to the cell, to thereby detach the cell from the culture surface.
Owner:CANON KK

Construction method of gastric cancer organoid culture system

The invention relates to the technical field of biology, and discloses a construction method of a gastric cancer organoid culture system, which comprises the following steps: preparation of a conditioned medium: culturing L-WRN cells and collecting the conditioned medium; preparing a gastric cancer organoid culture medium, and mixing the conditioned culture medium, the basic culture medium, a plurality of growth factors and additives; and extraction and culture of organoid: separating cells from gastric cancer tissues, mixing the cells with matrigel, and culturing by using the prepared culture medium. According to the method, the repeatability and the stability of the organoid model are improved, the response consistency of the organoid in drug screening is improved, and the reliability of the model in disease mechanism research and personalized medical application is guaranteed.
Owner:CHANGZHI PEOPLES HOSPITAL (CHANGZHI OCCUPATIONAL DISEASE PREVENTION & CONTROL HOSPITAL) +2

Method for generating cells of the t cell lineage with engineering broadly reactive human notch ligand

A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

ISOLATED LARYNGEAL Pou2f3-EXPRESSING CELL AND METHOD FOR MONITORING COUGH RESPONSE IN MOUSE

To provide an isolated cell capable of regulating cough.SOLUTION: The problem is solved by an isolated laryngeal PCC expressing Calhm3 protein.SELECTED DRAWING: None
Owner:KYOTO PREFECTURAL PUBLIC UNIV CORP +1

Variant AAV capsid polypeptides targeting the eye

PCT designated stageWO2026033140A1VectorsVirus peptidesHeterologousDisease
The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.
Owner:REVVITY GENE DELIVERY GMBH +1

Apparatus and methods for t-cell separation, activation, transduction and expansion

An apparatus and method for T-cell separation, activation, transduction and expansion. Three-dimensional (3D) bioreactors may be employed that include antibody coatings. Such 3D bioreactors can be employed for T-cell separation from peripheral blood mononuclear cells including attachment of T-cells to the 3D bioreactor surface for activation and transduction by lentivirus vectors to produce CAR T-cells. The CAR T-cells can then be expanded in a separate downstream bioreactor therein providing a scalable automated system.
Owner:SOUTHWEST RES INST

Method for preparing specific MHC haplotype-derived cell-binding virus

PendingCN121975744AIncrease screening positivity rateMicroorganism based processesViruses/bacteriophagesVaccine virusEmbryo
The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.
Owner:CHINA AGRI UNIV

CD24-expressing cell and applications of the same

To provide a cell including a cell expressing CD24, and related method of use and creation thereof.SOLUTION: Provided is an isolated cell including modification for increasing reduced expression of MHC class I and / or MHC class II human leukocyte antigens and expression of CD24 in a cell. In some embodiments, the cell includes reduced expression of MHC class I and MHC class II human leukocyte antigens.SELECTED DRAWING: None
Owner:SANA BIOTECHNOLOGY INC

Truncated recombinant l1 protein of human papillomavirus

The disclosure relates to a truncated recombinant L1 protein of Human papillomavirus (HPV), a recombinant polynucleotide encoding the protein, a recombinant vector comprising the polynucleotide, an isolated cell comprising the recombinant vector, a composition comprising the protein, and a method for producing the protein. The disclosure also relates to an HPV virus-like particle (VLP) comprising the protein, an immunogenic composition comprising the protein or the VLP, and a method for inducing an immune response to HPV in an individual.
Owner:SK BIOSCI CO LTD +1

Grid-free methods for making gamma delta t cells

PendingUS20260139225A1Gastrointestinal cellsEpidermal cells/skin cellsT cellThree dimensional scaffolds
The present disclosure provides, among other things, a method of isolating and expanding gamma delta (γδ) T cells, wherein the method comprises: (a) isolating non-hematopoeitic tissue by biopsy or explant, and (b) culturing the isolated non-hematopoeitic tissue in the absence of a three-dimensional scaffold or grid, thereby expanding and isolating gamma delta (γδ) T cells.
Owner:TAKEDA PHARMA CO LTD

Sorting biological and non-biological moieties using magnetic levitation

ActiveUS12485419B2Image enhancementImage analysisHeterogeneous populationMaterials science
A heterogeneous population of cells are separated and collected according to a method. The heterogeneous population of cells in a paramagnetic medium are placed in a fluidic channel in which the fluidic channel comprises two or more outlets. The heterogeneous population of cells in the fluidic channel are separated based on differences in magnetic susceptibility and density of the heterogeneous population of cells. Fluid comprising the separated cells is withdrawn from the two or more outlets using variable flow rates by fluidic pumps at respective ones of the two or more outlets simultaneously to fractionalize the fluid comprising the separated cells across the two or more outlets by manipulation of the variable flow rates relative to one another.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Embryogenesis factors for cellular reprogramming of a plant cell

Plant cell fate and development is altered by treating cells with cellular reprogramming factors. Embryogenesis inducing embryogenesis factor genes and / or morphogenic developmental genes are used as cellular reprogramming factors, specifically comprising polypeptides or polynucleotides encoding gene products for generating doubled haploids or haploid plants from gametes. Maize microspores treated by contacting the isolated cells with an exogenous purified, recombinant embryogenesis inducing embryogenesis factor gene products and / or morphogenic developmental gene polypeptide results in embryogenesis. The gametes of a maize plant develop into embryoids when transformed with a genetic construct including regulatory elements and structural genes capable of acting in a cascading fashion to alter cellular fate of plant cells. Embryogenesis factor proteins and / or developmental morphogenic proteins expressed from a genetic construct are used for ex situ treatment methods and for in planta cellular reprogramming.
Owner:PIONEER HI BREED INTERNATIONAL INC

Radiative cooling film

Provided in the present application is a radiative cooling film, comprising a base film layer, wherein the base film layer comprises a resin matrix, and a plurality of isolated cells, a plurality of separate first particles and a plurality of cell-enveloped second particles, which are all dispersed in the resin matrix. In the radiative cooling film using the technical solution of the present application, air in the cells in the base film layer is a substance with a low refractive index, the first particles and the second particles are each a substance with a high refractive index, and there are differences between the refractive index of the air in the cells and the refractive indices of the first particles and the second particles, thereby improving the reflectivity of the base film layer; by controlling the differences between the refractive index of the air in the cells and the refractive indices of the first particles and the second particles, high reflectivity is achieved; moreover, since the radiative cooling film of the present application does not contain a metal coating, signal shielding can be avoided, which is beneficial to the wide application of the radiative cooling film.
Owner:SVG TECH GRP CO LTD

Cartridge for processing biological samples and devices and methods thereof

Described are methods and systems for enhanced dissociation of cells from a solid biological tissue sample. In some embodiments, a self-contained cartridge apparatus includes a first chamber for receiving the tissue sample, enables ultrasonic energy from a transducer assembly of a processing unit to dissociate cells from the sample in the first chamber, and collect viable cells of interest from an aqueous suspension in a second chamber fluidly connected to the first chamber via a channel. In some embodiments, to enhance dissociation of viable cells, a filter device includes a tubular body configured to be telescopically inserted into a container containing the tissue sample in an aqueous fluid. The filter device also includes a cell-filter mesh that covers a bottom opening of the tubular body and that is configured to compress the tissue sample to expel cells from the sample when the filter device is fully inserted into the container.
Owner:CELLSONICS INC

Methods for isolating cells from a tissue sample.

The invention provides inter alia a method for enzymatic digestion of an extracellular matrix protein in a tissue sample, comprising the steps of:—providing an aqueous medium that comprises (i) a matrix metalloproteinase and (ii) a cation that is Ca2+ at a concentration of at least 2 mmol / L;—contacting said aqueous medium with a tissue sample that comprises an extracellular matrix protein under conditions that allow for enzymatic digestion of said extracellular matrix protein; wherein said tissue sample is a cartilage tissue sample.
Owner:CARTIREGEN BV

Human gastric cancer peritoneal metastasis ascites-derived cell line and application thereof

This invention belongs to the field of biomedical technology, specifically relating to a human-derived cell line for peritoneal metastasis of gastric cancer and its applications. The invention involves collecting ascites from gastric cancer patients and culturing it into organoids. These organoids are then transplanted subcutaneously into immunodeficient mice to form xenografts (PDOX). The transplanted organoids are digested and passaged in vitro to obtain a purified cell line. The primary isolated cell line is then inoculated into the peritoneal cavity of immunodeficient mice to induce the formation of metastatic ascites. Cells are extracted from the metastatic ascites and cultured again into organoids to construct human gastric cancer ascites cells, named BZGC. The cell line constructed in this invention has the ability to form 100% metastatic ascites in the mouse peritoneal cavity, fully simulating the entire process of ascites formation in gastric cancer peritoneal metastasis. The human-derived gastric cancer ascites cells described in this invention provide a stable, reliable, and highly clinically and pathologically similar in vitro and in vivo model for studying the mechanism of gastric cancer peritoneal metastasis, drug screening, and personalized treatment.
Owner:BEIJING CANCER HOSPITAL PEKING UNIV CANCER HOSPITAL

Native cell derived vesicles containing tumor suppressor proteins for therapy

A method of obtaining cell derived vesicles comprising an active wild-type p53 is disclosed. The method comprising: (i) isolating cell derived vesicles from a biological sample comprising cells; and (ii) treating the cell derived vesicles with a DNA damaging agent, or the method comprising: (i) treating cells with a DNA damaging agent; and (ii) isolating cell derived vesicles from a biological sample comprising the cells. A proteinaceous preparation comprising cell derived vesicles and a pharmaceutical composition comprising the proteinaceous preparation are also disclosed. Methods of treating a disease, disorder or condition associated with a mutant or a nonfunctional p53 protein and methods of inducing apoptosis of a target cell comprising a mutant or a nonfunctional p53 protein are also disclosed.
Owner:ANSERBIO LTD

Microfluidic device and method for separating cells

The invention relates to a microfluidic device. Said device has at least one magnetic marker, which is designed to bind to surface proteins of cells (30, 31), at least one mixing region, which is designed to bring the at least one magnetic marker into contact with the cells (30, 31), and at least one separating region (14), into which the cells (30, 31) can be introduced and which has at least one magnet (15), preferably on an upper side (16). A method for separating cells by means of the microfluidic device comprises bringing cells (30, 31) into contact with at least one magnetic marker in the mixing region, sedimenting the cells (30, 31) in the separating region (14), applying a magnetic field in the separating region (14), and discharging cells (31) marked with the marker from the separating region by means of a fluid flow (61).
Owner:ROBERT BOSCH GMBH

Tissue-derived extracellular vesicles and their use as diagnostics

The present disclosure relates to a method of isolating extracellular vesicles directly from human tissues. The invention further relates to a method of identifying disease and tissue specific membrane proteins on extracellular vesicles by membrane isolation and proteomic analysis. The invention further relates to methods of diagnosing diseases by capturing extracellular vesicles by the use of disease specific membrane proteins from body fluids, and detecting or analyzing molecular signatures (proteome, DNA, and RNA) on captured extracellular vesicles. Moreover, the present invention relates to kits, apparatus and software required for implementing aforementioned methods.
Owner:EXOCURE SWEDEN AB

Gas-filled microvesicles with ligand

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.
Owner:BRACCO SUISSE SA

A microfluidic chip system device and a method for capturing and separating extracellular vesicle subpopulations and applications

The application provides a microfluidic chip system device and a method and application of capturing and separating an extracellular vesicle subpopulation. The microfluidic chip system device comprises a capture chip and a magnetic separation chip for separating a captured sample; the capture chip comprises a capture flow channel and a J-shaped stopper arranged in the capture flow channel, an input end of the capture flow channel is adjacent to a sample inlet and a microsphere inlet, and an output end of the capture flow channel is provided with a sample outlet; the arc-shaped free end is used for blocking the sample flow to form a local micro-vortex; and the magnetic separation chip comprises a separation flow channel and a magnetic field device arranged on one side of the separation flow channel, and the separation flow channel is provided with a sample inlet, a buffer inlet and at least two sample outlets. The microfluidic chip can quickly capture and separate extracellular vesicles, and has small sample demand and low cost.
Owner:THE NAT CENT FOR NANOSCI & TECH NCNST OF CHINA

High-throughput single-cell analysis combining proteomic and genomic information

Disclosed herein are methods for single-cell sequencing. In some examples, the methods include enriching a sample comprising a plurality of cells for cells of interest to produce an enriched cell sample; isolating one or more cells of interest in the enriched cell sample; and obtaining sequence information of one or more polynucleotides from each of the one or more isolated cells. Obtaining sequence information may include generating a molecularly indexed polynucleotide library from the one or more isolated cells. Enriching the sample may include focusing cells of interest in the sample using acoustic focusing.
Owner:BECTON DICKINSON & CO